Phase I study of TrasGEX, a glyco-optimised anti-HER2 monoclonal antibody, in patients with HER2-positive solid tumours

PURPOSE: TrasGEX is a second-generation monoclonal antibody of trastuzumab, glyco-optimised to enhance antibody-dependent cellular cytotoxicity while fully retaining trastuzumab’s antigen-binding properties to human epidermal growth factor receptor 2 (HER2). A phase I dose-escalation study was condu...

Descripción completa

Detalles Bibliográficos
Autores principales: Fiedler, Walter, Stoeger, Herbert, Perotti, Antonella, Gastl, Guenther, Weidmann, Jens, Dietrich, Bruno, Baumeister, Hans, Danielczyk, Antje, Goletz, Steffen, Salzberg, Marc, De Dosso, Sara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6045773/
https://www.ncbi.nlm.nih.gov/pubmed/30018811
http://dx.doi.org/10.1136/esmoopen-2018-000381

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6045773/
https://www.ncbi.nlm.nih.gov/pubmed/30018811
http://dx.doi.org/10.1136/esmoopen-2018-000381

Ejemplares similares